Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA-026 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMA-026 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: 1. Healthy men and women 18 to 60 yrs with mild allergic asthma 2. only asthma med is short-acting bronchodilator used not more than twice weekly 3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction Exclusion Criteria: 1. Upper res...
IMA-026 is an investigational small molecule being studied for use in respiratory conditions. It has been evaluated in clinical trials involving healthy subjects and in patients with mild asthma. The drug is currently in Phase 1 clinical development and is not yet approved for any indication.
IMA-026 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development for respiratory indications, including asthma.
IMA-026 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for IMA-026 have been completed, and the drug is not currently in active clinical trials.
IMA-026 has been studied in three completed Phase 1 clinical trials. These include NCT00517348, a study in healthy subjects in the United States, NCT00528099, a study in healthy Japanese males in Japan, and NCT00725582, a study evaluating the effect of IMA-026 on allergen-induced late asthma response in patients with mild asthma.
Yes, IMA-026 has been studied in asthma. A completed Phase 1 clinical trial, NCT00725582, evaluated the effect of IMA-026 on allergen-induced late asthma response in patients with mild asthma. The trial enrolled 24 participants aged 18 years and older.
Yes, IMA-026 has been studied in healthy volunteers. Two completed Phase 1 trials, NCT00517348 and NCT00528099, enrolled healthy subjects. The first trial was conducted in the United States with 50 participants, and the second was conducted in Japan with 50 healthy Japanese males.